Natixis Advisors L.P. Grows Stock Holdings in Elevance Health, Inc. (NYSE:ELV)

Natixis Advisors L.P. increased its stake in Elevance Health, Inc. (NYSE:ELV) by 12.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 160,723 shares of the company’s stock after purchasing an additional 17,799 shares during the quarter. Natixis Advisors L.P. owned 0.07% of Elevance Health worth $75,790,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ELV. OFI Invest Asset Management purchased a new stake in shares of Elevance Health during the 3rd quarter valued at about $25,000. Alaska Permanent Fund Corp purchased a new stake in Elevance Health during the fourth quarter valued at approximately $31,000. Hexagon Capital Partners LLC raised its position in Elevance Health by 63.0% in the fourth quarter. Hexagon Capital Partners LLC now owns 75 shares of the company’s stock worth $35,000 after acquiring an additional 29 shares during the period. ORG Partners LLC purchased a new position in shares of Elevance Health during the 4th quarter worth $40,000. Finally, Orion Capital Management LLC bought a new stake in shares of Elevance Health during the 3rd quarter valued at $46,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Price Performance

ELV traded up $1.40 during trading on Friday, hitting $527.01. 819,415 shares of the company traded hands, compared to its average volume of 1,053,297. The stock’s 50-day simple moving average is $513.28 and its two-hundred day simple moving average is $488.46. Elevance Health, Inc. has a 1 year low of $412.00 and a 1 year high of $542.07. The company has a market cap of $122.49 billion, a PE ratio of 19.92, a P/E/G ratio of 1.16 and a beta of 0.79. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.54.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Thursday, April 18th. The company reported $10.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.54 by $0.10. The business had revenue of $42.27 billion for the quarter, compared to the consensus estimate of $42.49 billion. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The company’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $9.46 EPS. As a group, sell-side analysts anticipate that Elevance Health, Inc. will post 37.26 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 25th. Stockholders of record on Monday, June 10th will be given a dividend of $1.63 per share. This represents a $6.52 annualized dividend and a dividend yield of 1.24%. The ex-dividend date is Monday, June 10th. Elevance Health’s dividend payout ratio is 24.64%.

Analyst Upgrades and Downgrades

ELV has been the topic of several analyst reports. Barclays lifted their target price on Elevance Health from $584.00 to $621.00 and gave the company an “overweight” rating in a research report on Friday, April 19th. Truist Financial reaffirmed a “buy” rating and set a $600.00 price objective (up from $580.00) on shares of Elevance Health in a research report on Friday, April 19th. Jefferies Financial Group increased their target price on shares of Elevance Health from $602.00 to $604.00 and gave the stock a “buy” rating in a report on Friday, April 19th. Mizuho lifted their price target on shares of Elevance Health from $575.00 to $585.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Finally, Royal Bank of Canada increased their price objective on shares of Elevance Health from $574.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, April 19th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $587.42.

Insider Activity at Elevance Health

In other news, Director Ramiro G. Peru sold 753 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $500.00, for a total value of $376,500.00. Following the completion of the sale, the director now directly owns 9,109 shares of the company’s stock, valued at approximately $4,554,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Ramiro G. Peru sold 753 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $500.00, for a total value of $376,500.00. Following the completion of the sale, the director now owns 9,109 shares in the company, valued at approximately $4,554,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Felicia F. Norwood sold 14,111 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total transaction of $7,531,605.14. Following the transaction, the executive vice president now owns 31,460 shares in the company, valued at $16,791,460.40. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.